NasdaqCM - Delayed Quote USD

MyMD Pharmaceuticals, Inc. (MYMD)

2.8400 +0.0300 (+1.07%)
At close: April 26 at 4:00 PM EDT
2.8800 +0.04 (+1.41%)
After hours: April 26 at 7:54 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
16,360.2180
16,360.2180
15,282.7630
28,201.2470
8,296.1060
Operating Income
-16,360.2180
-16,360.2180
-15,282.7630
-28,201.2470
-8,296.1060
Net Non Operating Interest Income Expense
455.5700
455.5700
83.9910
-599.5530
-1,191.7180
Other Income Expense
11,904.6980
11,904.6980
1.4360
-1,088.2450
--
Pretax Income
-3,999.9500
-3,999.9500
-15,197.3360
-29,889.0450
-9,487.8240
Net Income Common Stockholders
-8,218.1630
-8,218.1630
-15,197.3360
-29,889.0450
-9,487.8240
Diluted NI Available to Com Stockholders
-8,218.1630
-8,218.1630
-15,197.3360
-29,889.0450
-9,487.8240
Basic EPS
-5.33
-5.33
-11.74
-25.50
-7.66
Diluted EPS
-5.33
-5.33
-11.74
-25.50
-7.66
Basic Average Shares
1,542.4530
1,542.4530
1,294.1990
1,167.2410
1,237.8410
Diluted Average Shares
1,542.4530
1,542.4530
1,294.1990
1,167.2410
1,237.8410
Total Operating Income as Reported
-17,123.0520
-17,123.0520
-15,282.7630
-28,809.7070
-9,487.9650
Total Expenses
16,360.2180
16,360.2180
15,282.7630
28,201.2470
8,296.1060
Net Income from Continuing & Discontinued Operation
-3,999.9500
-3,999.9500
-15,197.3360
-29,889.0450
-9,487.8240
Normalized Income
-15,904.6480
-15,904.6480
-15,198.7720
-28,800.8000
-9,487.8240
Interest Income
455.5700
455.5700
83.9910
8.9070
0.1410
Interest Expense
-92.6300
--
--
608.4600
1,191.8590
Net Interest Income
455.5700
455.5700
83.9910
-599.5530
-1,191.7180
EBIT
-16,360.2180
-16,360.2180
-15,282.7630
-29,280.5850
-8,295.9650
EBITDA
-16,360.2180
-16,360.2180
-15,282.7630
-29,280.5850
-8,277.6310
Reconciled Depreciation
--
--
--
--
18.3340
Net Income from Continuing Operation Net Minority Interest
-3,999.9500
-3,999.9500
-15,197.3360
-29,889.0450
-9,487.8240
Total Unusual Items Excluding Goodwill
11,904.6980
11,904.6980
1.4360
-1,088.2450
--
Total Unusual Items
11,904.6980
11,904.6980
1.4360
-1,088.2450
--
Normalized EBITDA
-28,264.9160
-28,264.9160
-15,284.1990
-28,192.3400
-8,277.6310
12/31/2020 - 1/23/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PXMD PaxMedica, Inc.
0.7398
+5.06%
 
NLSP NLS Pharmaceutics Ltd.
0.1367
+3.25%
 
DRMA Dermata Therapeutics, Inc.
0.3427
-3.74%
 
SONN Sonnet BioTherapeutics Holdings, Inc.
1.7700
+1.14%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%
 
VRAX Virax Biolabs Group Limited
0.6900
-1.71%
 
LGVN Longeveron Inc.
1.7500
+4.79%
 
ENVB Enveric Biosciences, Inc.
0.8950
-2.45%
 
TVGN Tevogen Bio Holdings Inc.
1.0000
+17.65%
 
SPRC SciSparc Ltd.
1.3200
+4.76%